Adult Dosing
Vasomotor symptoms and vulvar and vaginal atrophy due to menopause
- Start 0.3 mg PO qd, adjust dose as per response
- Alt: 0.3 mg PO qd in a cycle of 25 days on and 5 days off
Prevention of postmenopausal osteoporosis
- Start 0.3 mg PO qd, adjust dose as per response
- Alt: 0.3 mg PO qd in a cycle of 25 days on and 5 days off
Hypoestrogenism
Female hypogonadism
- 0.3-0.625 mg PO qd in a cycle of 3 wks on and 1 wk off
Female castration or primary ovarian failure
- 1.25 mg PO in a cycle of 3 wks on and 1 wk off
- May increase or decrease the dose according to severity of symptoms and response of the patient
Palliative treatment of breast cancer
Palliative treatment of prostate cancer
Notes:- In postmenopausal women with a uterus, add progestin for at least 12-14 days every 28 day cycle to reduce the risk to the endometrial cancer
- Use lowest effective dose of estrogen/progestin combination for shortest duration
Pediatric Dosing
- Safety and efficacy has not been established in children
- Estrogen therapy has been used for the induction of puberty in adolescents
[Outline]
- Estrogen alone or in combination with progestin therapy increases the risk of stroke, DVT, pulmonary embolism, and myocardial infarction [US Black Box Warning]
- Risk factors for arterial vascular disease and/or venous thromboembolism should be managed appropriately
- Estrogen alone or in combination with progestin therapy increases the risk of venous thromboembolism. Discontinue immediately if suspected.
- Discontinue the estrogen therapy 4-6 wks before surgery associated with an increased risk of thromboembolism, or require prolong immobilization
- Unopposed use of estrogens in women with intact uteri increases the risk of endometrial cancer 2-12 times greater than in non-users [US Black Box warning]
- Estrogens and progestins use in postmenopausal women increase the risk of breast cancer. Perform breast examination and mammogram yearly based on patient age, risk factors and prior mammogram results and advise patients to self examine every month
- Estrogen and estrogen/progestin therapy increases the risk of dementia in postmenopausal women 65 years of age and older [US Black Box warning]
- Increases the risk of gallbladder diseases by 2 to 4 fold in postmenopausal women receiving estrogen therapy
- Estrogen therapy causes severe hypercalcemia in patients with breast cancer and bone metastases. Discontinue the therapy and provide appropriate measures, if hypercalcemia occurs
- Retinal vascular thrombosis occurs in patients receiving estrogens. Discontinue the drug if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia or migraine. Permanently discontinue if papilledema or retinal vascular lesions are seen on examination
- Use of progestin with estrogen in continuous regimen lowers the incidence of endometrial hyperplasia, than would be induced by estrogen alone treatment. However there is possible increased risk of breast cancer, adverse effects on lipoprotein metabolism and impairment of glucose tolerance, with the use of progestins along with estrogens compared to estrogen-alone regimens
- Administration of estrogen therapy can exacerbate endometriosis
- Estrogen use causes increases in blood pressure, monitor BP at regular interval
- Estrogen therapy elevates the plasma triglycerides in patients with preexisting hypertriglyceridemia, leading to pancreatitis and other complications
- Use cautiously in patients with a history of cholestatic jaundice associated with past estrogen use or with pregnancy, discontinue the drug in case of recurrence
- Estrogen administration causes increased thyroid-binding globulin (TBG) levels. Patients on thyroid hormone replacement therapy receiving estrogen require increased doses of their thyroid replacement therapy. Monitor thyroid function regularly to maintain free thyroid hormone levels in an acceptable range
- Estrogen causes fluid retention, use cautiously in patients with conditions like asthma, epilepsy, migraine, and cardiac or renal dysfunction
- Use of estrogen alone for 5 or more years increases the risk of ovarian cancer
Cautions: Use cautiously in
- Renal impairment
- Cardiovascular diseases
- Hypertension
- Hypertriglyceridemia
- History of Cholestatic Jaundice
- Hypothyroidism
- Gallbladder disease
- Hyperparathyroidism
- Asthma
- Diabetes mellitus
- Epilepsy
- Migraine
- Severe hypocalcemia
- Surgery or prolonged immobilization
- Porphyria
- Systemic lupus erythematosus
- Hepatic hemangiomas
- Endometriosis
Pregnancy Category:X
Breastfeeding: Estrogen administration during breastfeeding interferes with lactation by decreasing the quantity and quality of the milk. Detectable amount is secreted in breast milk; manufacturer advises to use cautiously in nursing mother.
US Trade Name(s)
US Availability
Premarin
- TABS: 0.3, 0.45, 0.625, 0.9, 1.25, 2.5 mg
Canadian Trade Name(s)
Canadian Availability
Estrogen conjugated (generic)
- TABS: 0.3, 0.625, 0.9, 1.25 mg
C.E.S (generic)
- TABS: 0.3, 0.625, 0.9, 1.25 mg
Congest
- TABS: 0.3, 0.625, 0.9, 1.25, 2.5 mg
Premarin
- TABS: 0.3, 0.625, 1.25 mg
UK Trade Name(s)
UK Availability
Premarin
- TABS: 0.3, 0.625, 1.25 mg
Australian Trade Name(s)
Australian Availability
Premarin
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- Premarin 1.25 MG TABS [Bottle] (WYETH)
30 mg = $75.99
90 mg = $209.97 - Premarin 0.45 MG TABS [Bottle] (WYETH)
30 mg = $75.99
90 mg = $207.97 - Premarin 0.3 MG TABS [Bottle] (WYETH)
30 mg = $74.99
90 mg = $202.97 - Premarin 0.625 MG TABS [Bottle] (WYETH)
30 mg = $73.99
90 mg = $199.97 - Premarin 0.9 MG TABS [Bottle] (WYETH)
30 mg = $76.99
90 mg = $207.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.